Satsuma Pharmaceuticals Announces FDA Acceptance of 505 NDA for STS101, a Novel and Investigational Dihydroergotamine Nasal Powder Product for the Acute Treatment of Migraine

STSADelisted Stock  USD 1.10  0.01  0.90%   
About 61% of Satsuma Pharmaceuticals' investor base is looking to short. The analysis of current outlook of investing in Satsuma Pharmaceuticals suggests that many traders are alarmed regarding Satsuma Pharmaceuticals' prospects. The current market sentiment, together with Satsuma Pharmaceuticals' historical and current headlines, can help investors time the market. In addition, many technical investors use Satsuma Pharmaceuticals stock news signals to limit their universe of possible portfolio assets.
  
January 2024 PDUFA date expectedIf approved, STS101 would become the only DHE product evaluated in a randomized, placebo-controlled trial against modern outcome measures recommended by both the U.S.

Read at benzinga.com
benzinga news
  

Satsuma Pharmaceuticals Fundamental Analysis

We analyze Satsuma Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Satsuma Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Satsuma Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Shares Outstanding

Shares Outstanding Comparative Analysis

Satsuma Pharmaceuticals is currently under evaluation in shares outstanding category among its peers. Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.

Satsuma Pharmaceuticals Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Satsuma Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Satsuma Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Satsuma Pharmaceuticals by comparing valuation metrics with similar companies.

Peers

Satsuma Pharmaceuticals Related Equities

FBRXForte Biosciences   18.65   
0%
100.0%
KRONKronos Bio   10.34   
0%
55.0%
PEPGPepGen   6.69   
0%
35.0%
CTMXCytomX Therapeutics   6.25   
0%
33.0%
ERASErasca   5.04   
0%
27.0%
CINGCingulate   4.52   
0%
24.0%
CYCNCyclerion Therapeutics   2.78   
0%
14.0%
ASMBAssembly Biosciences   1.90   
0%
10.0%
SNTISenti Biosciences   1.42   
0%
7.0%
ACHLAchilles Therapeutics   0.94   
0%
5.0%
PMVPPmv Pharmaceuticals   0.63   
0%
3.0%
TILInstil Bio   0.00   
0%
0%
LRMRLarimar Therapeutics   0.00   
0%
0%
ADXNAddex Therapeutics   0.00   
0%
0%
ELYMEliem Therapeutics   1.30   
6.0%
0%
MNOVMediciNova   3.37   
18.0%
0%
PHVSPharvaris   7.49   
40.0%
0%
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.
You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.

Other Consideration for investing in Satsuma Stock

If you are still planning to invest in Satsuma Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Satsuma Pharmaceuticals' history and understand the potential risks before investing.
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
Equity Valuation
Check real value of public entities based on technical and fundamental data
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments